Esperion Therapeutics (ESPR) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

12 Health Care Stocks Moving In Friday's Pre-Market Session
BenzingaDec 13 16:06 ET
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $6
Moomoo NewsDec 13 13:31 ET · Ratings
Esperion Therapeutics Price Target Maintained With a $6.00/Share by Needham
Dow JonesDec 13 12:44 ET · Ratings
Express News | Esperion Enters Privately Negotiated Exchange And Subscription Agreements With Certain Holders Of 4.00% Convertible Senior Subordinated Notes Due 2025
BenzingaDec 13 06:01 ET
Esperion Announces $210M Convertible Debt Financing
Dow JonesDec 13 06:01 ET
Press Release: Esperion Announces $210 Million Convertible Debt Financing
Dow JonesDec 13 06:00 ET

Comments

10xStockPicks

6 hours ago

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

+2

7

1

3

10xStockPicks

6 hours ago

Must BUY Esperion Therapeutics Selling FDA Approved Statin Alternative Drugs Will Soon Be Acquired Suspect The Analysts.

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...

+2

1

10xStockPicks

13 hours ago

Esperion Is An Acquisition Target. Very Favorable New Debt Terms For Investors Offers Excellent Buying Opportunity 10x Upside Potential. Profitable in 2025.

$Esperion Therapeutics (ESPR.US) is the only pharmaceutical company with statin alternative medications Nexletol & Nexlizet for primary prevention with compounding monthly script growth in a massive market space, 21M Americans need statin alternative medications, either due to statin intolerance or need additional LDLC lowering. ESPR now...

3

2